The numbers coming out of IonQ tell two radically different stories, and the market has made its choice. On one hand, the quantum computing company posted a record first-quarter revenue of $64.7 million — a staggering 755% jump from a year earlier — and saw its order backlog balloon 554% to $470 million. On the other, its shares closed Friday at €28.84, down 3.8% on the day and nearly 39% lower over the past month. That disconnect has become the central drama for investors trying to decide whether this is a buying opportunity or a value trap.
The technical picture offers little comfort for the bulls. IonQ now trades roughly 37% below its 50-day moving average of €45.69 and nearly 29% beneath the 200-day average of €40.36. The 14-day relative strength index has sunk to 25.7, deep in oversold territory — a level that typically signals either outright capitulation or the early stages of a rebound. The stock has clawed back more than a quarter from its March low of €22.60, but last week’s 5% decline suggests that support level is being tested again. From the 52-week peak of €73.10 reached on October 13, 2025, the shares have shed roughly 61% of their value.
Much of that damage, however, has less to do with IonQ specifically and more with a sector-wide reckoning. Skepticism toward lofty valuations in quantum computing intensified in July, and the arrival of a new competitor — IQM Quantum Computers, which recently listed on the Nasdaq — gave investors another way to play the theme, fragmenting capital flows that had previously concentrated on IonQ. The same repricing has hit rivals Rigetti and D-Wave just as hard.
This dynamic explains why even strong earnings failed to lift the stock. IonQ’s first-quarter results, released in May, showed explosive revenue growth, yet the shares dropped on the news. The market has effectively decided that growth alone no longer justifies the current valuation. With an annualized 30-day volatility of 63%, IonQ remains a high-stakes bet where sentiment can shift violently from one session to the next.
The fundamental story, though, has not evaporated. The $470 million backlog — a 554% year-over-year surge — demonstrates that commercial demand is translating into long-term contracts rather than one-off deals. Analysts still see significant upside: the consensus price target of €60.76 implies a potential gain of 110.7% from Friday’s close. That unusually wide gap between current price and target reflects both genuine conviction in the multiyear thesis and the market’s current unwillingness to pay up for it.
Should investors sell immediately? Or is it worth buying IonQ?
Institutional investors are split on the direction. The California pension fund CalPERS has trimmed its position, while the Swiss National Bank and Bank of New York Mellon have added to theirs — a tug-of-war between caution and conviction that mirrors the broader debate.
The next major catalyst arrives on August 5, when IonQ is scheduled to report second-quarter results. That date has become a proving ground: investors who once accepted promises about the future now want to see tangible commercial progress. The company has secured new partnerships and hit key milestones with its chip-based hardware, but the heavy capital requirements continue to weigh on the valuation. Even prominent market commentators like Jim Cramer have publicly urged caution.
There is also a geopolitical angle that adds a layer of speculation. The U.S. Commerce Department recently launched a multimillion-dollar funding program for quantum technology — and IonQ was left out. That exclusion has fueled bets on prediction markets like Kalshi and Polymarket that the government may eventually take a direct equity stake in the company. The logic runs that IonQ’s deep ties to security and defense agencies could make its technology too strategically important to leave to market volatility alone. If Washington were to step in, the current market capitalization of €11.38 billion would be viewed through an entirely different lens.
For now, though, the stock remains caught between the promise of a quantum future and the impatience of a market that no longer rewards waiting. The RSI at 25.7 suggests sellers may be nearing exhaustion, and the recovery from the March low shows buyers have not abandoned the name entirely. But with the stock trading below every major moving average and the sector still in the throes of a painful repricing, this remains a conviction trade — not a simple technical bounce. Whoever buys here is betting that the valuation correction is closer to its end than its beginning, and that IonQ’s revenue and backlog growth will eventually force a change in market sentiment. The next trigger for that shift will likely come from new commercial project announcements — or from a broader return of risk appetite across the sector. Until then, the violent, sentiment-driven swings of recent weeks are likely to continue.
Ad
IonQ Stock: Buy or Sell?! New IonQ Analysis from July 25 delivers the answer:
The latest IonQ figures speak for themselves: Urgent action needed for IonQ investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 25.
IonQ: Buy or sell? Read more here...
